NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $3.14 -0.16 (-4.85%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.10 -0.04 (-1.40%) As of 06:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atea Pharmaceuticals Stock (NASDAQ:AVIR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atea Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.10▼$3.2950-Day Range$3.14▼$3.9052-Week Range$2.45▼$4.14Volume182,103 shsAverage Volume250,537 shsMarket Capitalization$249.19 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company Overview Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization. Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.AI Generated. May Contain Errors. Read More Atea Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreAVIR MarketRank™: Atea Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 746th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAtea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAtea Pharmaceuticals has a consensus price target of $6.00, representing about 91.1% upside from its current price of $3.14.Amount of Analyst CoverageAtea Pharmaceuticals has received no research coverage in the past 90 days.Read more about Atea Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.11% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 19.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.11% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 19.84%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.75 News SentimentAtea Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders18.10% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVIR Stock News HeadlinesAtea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comAtea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. | Banyan Hill Publishing (Ad)Atea Pharmaceuticals’ Earnings Call Highlights HCV ProgressAugust 13, 2025 | msn.comAtea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comAtea (AVIR) Q2 Loss Narrows 8%August 7, 2025 | fool.comAtea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comAtea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025July 31, 2025 | globenewswire.comSee More Headlines AVIR Stock Analysis - Frequently Asked Questions How have AVIR shares performed this year? Atea Pharmaceuticals' stock was trading at $3.35 at the beginning of 2025. Since then, AVIR shares have decreased by 6.3% and is now trading at $3.14. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.02. Read the conference call transcript. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $253 million in an IPO on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. Who are Atea Pharmaceuticals' major shareholders? Atea Pharmaceuticals' top institutional investors include Geode Capital Management LLC (2.25%), JPMorgan Chase & Co. (0.82%), Hsbc Holdings PLC (0.25%) and American Century Companies Inc. (0.22%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Franklin M Berger, Bruce Polsky and Wayne Foster. View institutional ownership trends. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atea Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO). Company Calendar Last Earnings8/07/2025Today9/15/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVIR CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Atea Pharmaceuticals$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+91.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$168.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.55% Return on Assets-30.47% Debt Debt-to-Equity RatioN/A Current Ratio19.17 Quick Ratio19.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.20 per share Price / Book0.60Miscellaneous Outstanding Shares79,360,000Free Float64,994,000Market Cap$249.19 million OptionableOptionable Beta0.25 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AVIR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.